Navigation Links
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Date:5/21/2013

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 – 4:30 PM.  The presentation will describe the results of a first-in-human study of MacroGenics' next-generation anti-HER2 monoclonal antibody, margetuximab, which is being developed to treat HER2-expressing tumors.  

MacroGenics has optimized the Fc region of margetuximab to increase cancer cell killing via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).  Margetuximab also has shown improved control of tumor growth in human tumor xenograft models in mice as compared to that of anti-HER2 antibodies with a wild type Fc region.  A development goal for margetuximab is to enable the treatment of a broader population of patients than those eligible for treatment with current HER2-targeted therapies.

MacroGenics also announced that the first patient has received study drug in a Phase 2 clinical study evaluating margetuximab in patients with metastatic breast cancer.  This study is designed to evaluate the activity of margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of the oncoprotein, HER2, represented by a 2+ score by immunohistochemistry.  These tumors must also lack evidence of HER2 gene amplification as determined by FISH testing.  The trial is being conducted at six sites across the United States.  For more information on the clinical trial, please see www.clinicaltrials.gov.

"To date, the results of our Phase 1 s
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
2. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
3. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
4. SoundConnect Announces Microsoft Lync Release in Canada
5. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
6. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
9. DNA Genotek Inc. Announces Spit for Africa Program
10. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
11. Discovery Labs Announces Completion of $14.25 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 9 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" ... an,annual and special meeting held today, its ... (the "Arrangement") involving,among others, Chromos, Calyx Bio-Ventures ... Modatech Systems Inc. ("Modatech") under section,288 of ...
... the second consecutive,year, MedNet Solutions, a leading healthcare ... been recognized by,Inc. magazine as being among the ... growth over the past four years,MedNet was the ... area, and fifth among healthcare-related software companies in ...
... A seven and a half-year study,conducted in the In ... Health Network found that the use of ultraviolet C ... clinically significant,impact on clinical pregnancy rates (CPR). In presenting ... for Reproductive Medicine (ASRM),Kathryn C. Worrilow, Ph.D. reported that ...
Cached Biology Technology:Chromos announces shareholder approval of Arrangement 2Chromos announces shareholder approval of Arrangement 3MedNet Solutions Again Recognized as one of the Fastest Growing US Companies 2Germicidal UVC Lights Improve Clinical Pregnancy Rates for IVF Lab, New Study Finds 2
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
(Date:4/17/2014)... many serious conditions such as heart disease, epilepsy and ... therapies. Unfortunately, there is still much scientists do not ... and unexpected insight into the structure of sodium channels ... - which are responsible for ,fine-tuning, the activity of ... recent edition of the Journal of Biological Chemistry ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Structure of sodium channels different than previously believed 2
... American Association for the Advancement of Science (AAAS) will ... impact and contributions towards the production of African American ... associate dean of graduate studies and international programs in ... State University in Jackson, Miss., will receive his award ...
... NY (February 12, 2014) A team of Columbia ... Cardoso, MD, PhD, has found the first direct evidence ... postnatal airway hyperresponsiveness, a hallmark of asthma. The study, ... essential vitamin while the lung is forming can cause ...
... (Biological Impacts of Ocean Acidification) are developing a ... acidification and climate change with their economic and ... the Norwegian fishing industry and tourism sector, the ... key aspects for their assessment. During the ...
Cached Biology News:2013 AAAS Mentor Award goes to Paul B. Tchounwou of Jackson State University 22013 AAAS Mentor Award goes to Paul B. Tchounwou of Jackson State University 3Prenatal vitamin A deficiency tied to postnatal asthma 2Prenatal vitamin A deficiency tied to postnatal asthma 3Meeting the eye-witnesses of ocean change 2Meeting the eye-witnesses of ocean change 3
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
... Lacks the mycobacteria found in ... For this reason, Incomplete, Freund's ... Adjuvants may be used to produce water-in-oil emulsions ... stimulate high and long-lasting antibody responses which can ...
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
Biology Products: